Monthly Archives: June 2022

Kangstem Biotech said Monday that it has voluntarily withdrawn a phase 1 and 2a clinical trial investigational new drug (IND) approval for "FURESTEM-OA Kit Inj.," a candidate material for stem cell-based osteoarthritis (OA) treatment.

The company decided to withdraw its plans after determining that it required further data reinforcement concerning establishing a cell bank for clinical trial drugs after the government started enforcing the "Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act."

The Ministry of Food and Drug Safety had requested the results of the adventitious virus-negative test from Kangstem Biotech. The test proves that even when the test drug used in clinical trials is manufactured using a cell bank, the quality and safety are the same, and there is no scientific risk factor.

Accordingly, the company confirmed that there is no adventitious virus by completing the virus test by the qPCR test method following the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) regulations at Korean institutions.

Also, the company entrusted the test to the additional culture method of Charles River, an American consignment testing institution.

However, the company decided to voluntarily withdraw its IND approval, confirming it would be difficult to complete the test and analysis to secure additional data within the administrative processing period required for review of the clinical trial plan approval period.

"The IND application for the FURESTEM-OA Kit was for the first clinical trial for a stem cell-based fusion drug under the Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act," Kangstems Clinical Development Division Director Bae Yo-han said. "Therefore, the IND approval process was somewhat delayed as the Ministry of Food and Drug Safety had to review its safety from various angles thoroughly."

During the delay period, additional test data that did not need to be initially submitted became a requirement, Bae added.

However, Bae stressed that the Ministry of Food and Drug Safety also believes that there are no additional problems in the clinical trial plan itself, other than a review on securing safety related to adventitious factors by ingredients used in the manufacturing process of the drug.

"Therefore, the company is aiming to re-apply for the phase 1 and 2a IND of the FURESTEM-OA Kit in July at the earliest and get approval within October," he said.

Due to the company's explanation, the company's shares rebounded on Wednesday after dropping about 5 percent the previous day.

As of 1:40 p.m. Tuesday, the company's stock price stood at 2,860 won ($2.22) per share, up 2.33 percent from the previous trading day.

Continued here:
Kangstem Biotech withdraws trial application for stem cell-based osteoarthritis treatment - KBR

Published 06-16-22

Submitted by Rockwell Automation

In an important step toward integrating biomanufacturing science with production techniques, Rockwell Automation (NYSE: ROK) announced the openingof the Rockwell Experience Center at the Advanced Regenerative Manufacturing Institute (ARMI) in Manchester, N.H. on June 8.

The new center will help teach ARMIs members, including physicians and researchers, how to leverage smart manufacturing to scale regenerative medicine products so they can be delivered to more people faster. ARMI's process relies on smart automation to help to mass produce safe and reliable biological products such as human tissues, skin, cartilage, and replacement organs. The center includes equipment from Rockwell, Air Science, Cytiva, Festo, and HID Global.

To say that the addition of the Rockwell Experience Center at the ARMI|BioFabUSA facility will be impactful to the area of regenerative medicine would be an understatement, said inventor, FIRST Robotics Founder and ARMI Executive Director Dean Kamen. By opening this center, we are able to demonstrate the baseline tools by which different types of human tissues and organs can be manufactured at scale. It's life changing.

Learn more about how ARMI and Rockwell are helping scientists create replacement tissues and organs. Watch this video and read this story.

About Rockwell Automation

Rockwell Automation, Inc.(NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 25,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visitwww.rockwellautomation.com.

More from Rockwell Automation

See the original post here:
Using Smart Manufacturing Technology to Scale Regenerative M - CSRwire.com

ReportLinker

Global Nanomedicine Market, By Nanomolecule Type (Nanoparticles, Nanoshells, Nanodevices, Nanotubes), By Nanoparticle Type (Polymer-based, Lipid-based, Nanocrystals, Inorganic, Others), By Application (Drug Delivery, Vaccines, Diagnostic Imaging, Regenerative Medicine, Others) By Disease Indication (Oncological Diseases, Infectious Diseases, Orthopedic Disorders, Cardiovascular Diseases, Others), By Region and Competition Forecast & Opportunities, 2027

New York, June 20, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nanomedicine Market, By Nanomolecule Type, By Nanoparticle Type, By Application By Disease Indication, By Region and Competition Forecast & Opportunities, 2027" - https://www.reportlinker.com/p06287479/?utm_source=GNW

The global nanomedicine market is expected to grow at an impressive CAGR of 8.28% in the forecast period, 2023-2027, to reach USD242655.19 million by 2027. The market is driven by the factors such as the growing healthcare expenditure and increased demand for personalized medicines. The massive prevalence of chronic and lifestyle disorders such as cancer and cardiovascular diseases across the globe is accelerating the application of nanomedicine in various healthcare applications. Also, the high-end investments in research and development activities by public and private players to find novel solutions for drug delivery and increase the effectiveness of drugs are expected to create lucrative growth opportunities for the global nanomedicine market in the forecast period.Nanomedicines are considered very effective in treating chronic diseases such as cancer, dementia, and diabetes as they fuel the metabolism of medications in the body.They deliver the drugs at the target site in the right proportion.

The markets availability of nanomedical products such as DNA probes, nanosensors, and nanoparticle-based imaging agents is increasing the demand. However, the high cost associated with the nanomedicine manufacturing process and research and development activities may hinder the global nanomedicine market in the forecast period.The global nanomedicine market is divided into nano molecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape.Based on application, the nanomedicine market is divided into drug delivery, vaccines, diagnostic imaging, regenerative medicine, and others.

Drug delivery applications dominated the market in 2021 and captured 30.23% of the overall market share. This segment is expected to maintain its dominance over the next five years. The rise in awareness about the benefits of nanomedicine in drug delivery applications and the increased prevalence of diseases drives the demand for nanomedicines for drug delivery applications.The major market players operating in the global nanomedicine market are Pfizer Inc., Janssen Pharmaceuticals, Sanofi S.A., Amgen Inc., Moderna, Inc., Novo Nordisk A/S, Genentech, Inc., Celgene Corporation, Vifor Pharma Group, Teva Pharmaceutical Industries Ltd., among others.

Years considered for this report:

Historical Years: 2017-2020Base Year: 2021Estimated Year: 2022Forecast Period: 2023-2027

Objective of the Study:

To analyze the historical growth and the market size of the global nanomedicine market from 2017 to 2021. To estimate and forecast the market size of the global nanomedicine market from 2023 to 2027 and growth rate until 2027. To classify and forecast the global nanomedicine market is divided into nanomolecule type, nanoparticles type, application, disease indication, regional distribution, and competitive landscape. To identify drivers and challenges for the global nanomedicine market. To examine competitive developments such as expansions, new product launches, mergers, and acquisitions, etc., in the global nanomedicine market. To conduct pricing analysis for the global nanomedicine market. To identify and analyze the profile of leading players operating in global nanomedicine market.The analyst performed both primary as well as exhaustive secondary research for this study.Initially, the analyst sourced a list of leading nanomedicine manufacturers across the globe.

Subsequently, the analyst conducted primary research surveys with the identified companies.While interviewing, the respondents were also enquired about their competitors.

Through this technique, the analyst could include the nanomedicine manufacturers who could not be identified due to the limitations of secondary research. The analyst examined the nanomedicine manufacturers, distribution channels and presence of all major players operating in the global nanomedicine market all over the world.The analyst calculated the global nanomedicine market size using a bottom-up approach, where data for various regions was recorded and forecasted for the future years. The analyst sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size.

Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

Key Target Audience:

Nanomedicine manufacturers/ suppliers/ distributors Government bodies such as regulating authorities and policy makers Organizations, forums, and alliances related to nanomedicine Market research and consulting firmsThe study is useful in providing answers to several critical questions that are important for industry stakeholders such as nanomedicine manufacturers, suppliers, distributors, and other stakeholders. The report would enable the stakeholders in strategizing investments and capitalizing on emerging market opportunities.

Report Scope:

In this report, global nanomedicine market has been segmented into following categories, in addition to the industry trends which have also been detailed below: Nanomedicine Market, By Nanomolecule Type:o Nanoparticleso Nanoshellso Nanodeviceso Nanotubes Nanomedicine Market, By Nanoparticles Type:o Polymer-basedo Lipid-basedo Nanocrystalso Inorganico Others Nanomedicine Market, By Application:o Drug Deliveryo Vaccineso Diagnostic Imagingo Regenerative Medicineo Others Nanomedicine Market, By Disease Indication:o Oncological Diseaseso Infectious Diseaseso Orthopedic Disorderso Cardiovascular Diseaseso Others Nanomedicine Market, By Region:o North AmericaUnited StatesCanadaMexicoo EuropeGermanyFranceUnited KingdomItalySpainDenmarko Asia PacificChinaJapanIndiaAustraliaSouth KoreaMalaysiaVietnamo South AmericaBrazilArgentinaColombiao Middle East & AfricaTurkeyIsraelSouth AfricaSaudi ArabiaUAEKuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global nanomedicine market.

Available Customizations:

With the given market data, we offers customizations according to a companys specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).Read the full report: https://www.reportlinker.com/p06287479/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Go here to read the rest:
Global Nanomedicine Market, By Nanomolecule Type, By Nanoparticle Type, By Application By Disease Indication, By Region and Competition Forecast &...

A battered woman. A wounded warrior. An injured football player.

All may come from different worlds. Yet, they may all be connected by one thing traumatic brain injury.

In the United States, traumatic brain injury, or TBI, affects approximately 1.7 million people. Most injuries occur in adolescents 15-19 and in older adults 65 and older. In 2020, more than 64,000 TBI-related deaths were reported in the country.

Across the globe, hundreds of researchers have dedicated careers to studying and testing methods to improve treatment options for TBI survivors. Michael Detamore, a biomedical engineering researcher at the University of Oklahoma, was recently awarded $640,000 from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health to fund his project: Single stage surgical intervention for treatment of severe traumatic brain injury.

According to a release, patients who suffer a severe TBI must undergo two surgeries one to remove a part of the skull to allow the brain to swell and another surgery to replace the missing bone after brain swelling subsides.

Detamore and his team may have found a way to reduce the number of surgeries to just one, which could be a very big deal.

When a doctor does a hemicraniectomy, removing the top part of the skull, there must be a second surgery, Detamore said. In a second surgery, they can either put back in a printed or metal plate or the original bone if it was preserved. But there is always a second surgery to fill that gap.

Traumatic brain injurys after-effects memory loss, dizziness, and depression can occur until the missing bone is replaced in a second surgery. Detamore believes patients can be treated through a single-stage surgical procedure using hydrogel materials.

The key to our approach is a new class of hydrogel materials, where natural materials including demineralized bone matrix, devitalized cartilage or devitalized tendon are themselves the crosslinkers of the hydrogel, Detamore said. Our material consists of a paste-like precursor solution of tissue particles and hyaluronic acid that behaves as a paste that a surgeon can easily sculpt into the open calvarial defect area. The material remains flexible so the brain can swell, and then be replaced by regenerating bone, eliminating the need for the second surgery.

Hydrogel starts as paste, like toothpaste or peanut butter, that the surgeon can spread and contour into the defects of the brain. When a light is shone on the paste, it sets. Its not solid like wood, its like Jell-O. Its flexible, but its solid.

Detamore recognizes that hundreds of researchers are studying TBI through different lenses such as psychological and pharmacological.

OUs research is unprecedented though, he said.

Our team is the first to use regenerative medicine as a tool to help treat traumatic brain injury.

Detamores interest in the field started about 15 years ago when he served on a masters thesis committee where a students work focused on paste-like biomaterials.

I remember thinking that the students research would be perfect for bone regeneration and it sounded like I was joking, but I was very serious and followed up on it, he said. That effort led to an NIH grant with Cory Berkland, of the University of Kansas, as principal investigator.

Flash forward to present day and Detamore is a principal investigator of this current NIH project. Berkland, Dr. Brian Andrews, a surgeon who specializes in head and neck surgery at the University of Iowa Hospitals and Clinics, and neuroscientist and the other principal investigator Randolph Nudo, University of Kansas Medical Center, also are involved in the initiative.

Current TBI surgical management hasnt changed much since the injury was first identified in 1908.

This means that unlike almost every other medical condition, there have been few to no advances to treat TBI, which is a debilitating and prevalent problem in our society. Moreover, there are few non-surgical options such as systemic drug therapy to treat TBI, Andrews said.

He wants his work to fill the gaps.

Today, the research team has eight key personnel.

OU is doing more of the work on the material side and the group at the University of Kansas are doing more of the work with the traumatic brain injury model. Neither university could do this project on its own, he said. Its the synergistic combination that makes this project possible and that is also what makes that unique niche possible. We are the only ones in the world doing this because of the different types of people coming together.

In 2016, Detamore was hired to lead the newly formed Stephenson School of Biomedical Engineering in the Gallogly College of Engineering at OU. He and then-student Jakob Townsend, continued to move the TBI research project forward. Townsend has since graduated from OU and continues to contribute to the project emphasizing that TBI affects more than just military personnel and athletes. It affects kids.

We need something that can be implanted into a child and grow with the child over time, he said. Hydrogel materials can accomplish that. When we talk with surgeons, we continue to learn of even more areas where hydrogels can make an impact and help patients. Each member of the team looks forward to seeing how far this project can go.

Read this article:
OU researcher works to transform care for traumatic brain injury - Journal Record

Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.

Cardiologist Dr. Joshua Hare is one of those scientists, and hes both the co-founder and chief scientific officer of Longeveron Inc. LGVN, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Hes also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.

The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019.

Hare recently spoke at a TEDx Miami conference on aging and the advancements his team is making toward slowing down and possibly reversing the aging process.

Too often when people age, they become frail and disabled, reducing the quality of life for those who live well into their golden years, Hare said. He said prolonging a persons life without restoring their health really isnt living at all.

He opens his talk by discussing life in the 1880s and how people only lived to be in their 40s. He discussed how childbirth could be a death sentence for many and how the discovery of germ theory led to more successful pregnancies and childbirth as the human lifespan doubled over time.

He likens this discovery to regenerative medicine and how harvesting human stem cells can be used as medicine in the future.

Around the world, top medical scientists are studying the biology of aging, just as scientists in 1880 were trying to understand the biology of bacteria, Hare said.

He explained how medical scientists are studying changes that occur during the aging process and how the entire body is affected from the changes in blood vessels to a weakened immune system and ones outward appearance.

He explains that reservoirs made of stem cells improve the health of vital organs and allow tissues to heal by replacing dying cells that are slowly diminishing. He poses the following questions:

Almost eight years ago, Hare started Longeveron and began testing stem cells as one of many treatments to find a possible fountain of youth.

When we think about aging, it's not just the longevity of life, Hare said. It's not just how long we live. But it's also the quality of those years as human lifespan has increased. Unfortunately, the period of time where we're disabled at the end of our life has also increased.

Anti-aging treatments should not be focused on the length of human life but rather on the quality of human life, Hare said, noting that people around the world are at risk of frailty, chronic disease and poor health as they age.

Longeveron says its on a mission to create a paradigm shift in science and medicine, developing therapies derived from culture-expanded and isolated medicinal signaling cells (MSCs) extracted from the donated bone marrow of healthy young adults.

Grown in a laboratory, these multipotent MSCs reportedly have unique therapeutic properties, including homing to inflammation and tissue damage sites. By stimulating these cells, its sometimes possible to maintain organ health, repair deteriorating tissues and restore immune function.

The companys website explains this phenomenon:

As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

Longeverons current areas of research focus include:

Hare explained how CAR T-cell therapy can kill cancer and said he is ready to lead the new frontier in developing safe and effective cell therapies for some of the most challenging diseases and conditions associated with aging.

Companies like Statera Biopharma Inc. STAB, Concert Pharmaceuticals CNCE, Annovis Bio ANVS, Cassava Sciences SAVA, and Lineage Cell Therapeutics Inc. LCTX might be right by his side.

To learn more about Longeveron and how its using allogeneic stem cells to attempt to create a host of therapies for healing and aging, check out https://www.longeveron.com.

Watch the TEDx Talk here: https://loom.ly/1xhSmBY

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Image by Mehmet Turgut Kirkgoz on Pixabay

Originally posted here:
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It - - Benzinga

Miami, FL, June 21, 2022 (GLOBE NEWSWIRE) -- Grand Havana, Inc. (OTC Pink: GHAV) (GHAV or the Company), is pleased to announce the signing of an agreement (Agreement) with Can B Corp, Inc. (OTCQB: CANB) (CANB), a health and wellness company specializing in developing, producing and selling hemp-derived cannabinoid products.

Under the terms of the Agreement, Havana will assist Can B in the research and development of a proprietary CBD additive (Additive) that Havana will add to their production process to allow the CBD to be infused in the coffee once brewed. The actual Additive manufacturing will be done in Can Bs Miami, Florida R&D lab and processing center or other production facilities as needed.

To expedite time to market, Havana intends to leverage its scalable network of manufacturing and distribution centers throughout Florida in addition to Can B commitment to add the CBD Coffee to its product offerings. The new CBD infused coffee will be available in Havanas optimum blend medium dark roast in a 12-ounce double zipped bag with an air valve for freshness.

Furthermore, the company has signed a partnership agreement with Peter Michael MD MBA a certified specialist with the ability to provide medical marijuana card evaluations. Under the agreement, Dr. Peter Michael will be the face of the 12oz Grand Havana CBD Infused coffee.

Grand Havana is now taking pre-orders on our company website http://www.grandhavanacoffee.com

Tanya Bredemeier Chief Executive Officer of Grand Havana, Inc. commented, After numerous discussions and much consideration, the Company is happy to have finally found the right commercialization and brand development partner with Can B to bring CBD infused coffee product to fruition. Ms. Bredemeier further added We welcome Dr. Peter Michael onboard and look forward to branding our CBD coffee as the best products in the market we are using the Companys flagship dark roast Cuban style espresso brand, Grand Havana, will also be the first to offer CBD-infused espresso, which will be made available to consumers as soon as possible in our cafes and online. Havana currently services over 1,000 retailers in the southeast market and is looking to expand.

Marco Alfonsi, Can Bs Chief Executive Officer, stated, This is a significant expansion milestone for our company as coffee is still Americas favorite beverage and its popularity continues to grow. Added Mr. Alfonsi, the CBD opportunity with Havana is evidence of the growing market wide expansion into the CBD beverage opportunity and we are glad to be linked with Grand Havana, Inc.

Dr. Peter Michael states As a certified regenerative medicine and anti-aging specialist I have been using CBD to help my patients in a variety of ways. The CBD, produced by CANB Corp., blended with Grand Havana espresso delivers an effective combination of flavor, focus and energy. The product is designed to enhance alertness, relieve stress and provide energy through the synergistic effects of caffeine and CBD in dopamine and serotonin.

About Grand Havana, Inc.

Grand Havana is a coffee company headquartered in Miami, Florida The Capital of Espresso in the US.

Grand Havana products are distributed by Sysco, Ambassador Foods and Amazon. We proudly serve our coffees in corporate offices, airports, universities, non-traditional avenues, supermarkets, convenience stores, hotels, online marketplaces and in our fresh and exciting chain of Grand Havana Caf coffee shops across the US. With more than 10 million cups of coffee served nationwide, Grand Havana is the choice of consumers when it comes to delving into the nostalgia and essence of the best cup of Cuban coffee, thus offering a b2b solution that provides our high-quality coffee product delivered and reliable with timely technical service.

For more information, visitwww.Grandhavanacoffee.com, call 1.800.608.5441, or emailorders@grandhavanacoffee.comFind out more about the company atwww.Facebook.com/grandhavanacoffee,twitter.com/grandhavcoffee1, orwww.instagram.com/grandhavanacoffee/

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. CanB Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high quality products, please visit: Canbiola.com andwww.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: http://www.CanBCorp.com

About Dr. Peter Michael

Dr. Peter Michael is a certified specialist with the ability to provide medical marijuana card evaluations a graduate of the University of Miami Miller School of Medicine. He completed his internal medicine residency at Howard University Hospital and his physical medicine and rehabilitation (PM&R) at the University of Miami Miller School of Medicine. In 2016, he completed an interventional pain management fellowship at the Florida Spine Institute, and in 2017, a interventional pain and regenerative sports medicine fellowship with Marko Brodor MD.Dr. Michael additionally received his Master of Business Administration from University of Miami School of Business in 2011, and has been published in various journals and conferences.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of latest information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Go here to see the original:
Grand Havana, Inc. Launches Grand Havana CBD Infused Coffee with Can B Corp, Inc. Adding Dr. Peter Michael as its Brand Ambassador to represent Grand...

Dr. Natthapat Benz Minchaiynunt from Alpha Medical Clinic on his vision for the future of aesthetic services, mastering the PICO Laser, and offering clients nothing but the very best.

Known for impeccably precise treatments and top-of-the-line equipment, a visit to Alpha Medical Clinic Thailands largest private aesthetic clinic is unlike any other. Advanced technologies provide the highest standards of safety and quality, while welcoming VIP private rooms make the space reminiscent of a luxury hotel.

The true highlight, however, is the founder himself: Thailands first and only specialist with triple American Board certifications in Aesthetic Medicine (AAAM), Anti-Aging and Regenerative Medicine (ABAARM), and Laser Surgery (ABLS) and a Fellow in Aesthetic Medicine (FAM) Dr. Natthapat Benz Minchaiynunt. He is the most popular go-to specialist in Thailand for Picosecond Laser, with more than 500 patients a month coming only for this specific treatment. Prominent society faces book weeks ahead to be treated by him personally, and the clinic is ranked among Thailands top clinics for fillers.

Many things brought us to where we are today, Dr. Benz notes, our philosophy, knowledge and world-class techniques adapted from top professors around the world. He confesses that Alpha Medical Clinic was initially built for him to share his expertise with close friends and family, but over time he felt an ethical responsibility to open it to the public.

We started by inviting people we knew, he explains, they got much better results compared to other clinics, started referring us to one another through word of mouth, and thats how we grew. It really boils down to providing the best result for your clients.

In this case, the best is almost an understatement. Alpha Medical Clinic is home to some of the most advanced aesthetic equipment on the market, such as the Discovery Pico Laser 1.8GW. Very few of these machines exist in Thailand, as most hospitals and clinics use Discovery Pico Derm (Start) 1.3GW (which has less peak power and pulse energy), Thermage FLX, Thermage CPT, Ulthera SPT and other lasers.

Treatment plans are personalised to individual needs, identified through detailed consultations and a 3D augmented reality (AR) machine, which can scan under the inner skin (areas that are impossible for a general practitioner to be able to see). We are able to utilise all laser machines to their fullest potential. At such high power usage, with the special technique and technology we have, it is completely safe for the skin, with no side effects, and that also reduces the number of treatment sessions required, Dr. Benz explains. We also use it to simulate facial reshaping, whether its Thermage to reduce the cheek width by specific millimeters, or to lift the facial skin using Ulthera treatments.

While its common in Thailand to visit an aesthetic clinic with specific treatments in mind, a large part of Dr. Benzs role is advising his patients on the ideal course of action, which is not necessarily what they book an appointment for. Not every treatment is going to be the right one for you. My job is to make sure your face is suitable for a specific procedure, and that it will help you get the results youre looking for whether with laser, a face lift, or injections that are the most effective and safest.

Although advanced technology is central to Alpha Medical Clinic, Dr. Benz believes knowledge and expertise is what sets it apart. My expertise is my technique, which I gained through research, and combining what Ive learned from industry experts abroad. Aside from having the best technology, knowing how to use it, and which parameters to set, are just as important.

Such techniques range from a scab-free tattoo removal approach, to special methods for healing acne scars. Dr. Benz refers to this as combi- RF, where Pico Laser and Thermage are combined to effectively remove scarring, and smoothen the skin.

Picosecond Lasers are good for treating acne scars. Thermage is a non-invasive radiofrequency (RF) therapy that stimulates collagen production, lifting and changing your face structure. Combined, you can remove pimples, while evening out the skin.

The Pico Laser remains Alpha Medical Clinics top treatment, with Dr. Benz as the clinics laser expert. Pico Laser is the God of Skin Lasers amongst industry insiders, he remarks. If you know how to utilise its full potential, it can do anything, from reducing wrinkles, to removing melasma, freckles or stretch marks, and brightening your skin. Whatever the objective of our patients are a smooth skin without pores, or a clear skin our Pico laser is the answer.

His expertise makes Alpha Medical Clinic one of the only places where clients can enjoy visible, long-lasting results without side effects. Doctors are usually wary of administering heavier treatments because theyre worried about side effect such as melasma and PIH. However, I have a special technique that doesnt stimulate PIH and other side effects.

Today, Dr. Benz and his team of specialists continue raising the bar for aesthetic and laser services in Thailand, debunking misconceptions and providing clients with superior service. There are a lot of misunderstandings in this industry, he says. For example, people usually think that any doctor should be a filler and laser expert, but this is not true. Doctors who inject fillers or perform good laser therapies should be specialists very well trained in this field. Other countries, like the USA, have specific boards for Aesthetic Medicine and Cosmetic Laser Surgery. We dont have such certification in Thailand yet, but Im hoping that changes soon.

When asked about his future goals, Dr. Benz shares his plan to expand into cosmetic surgery and other departments. As with Alpha Medical Clinic, I want to ensure that everything we offer is of superior quality and well rounded.

To find out more, visit alphamedicalclinicthailand.com.

Excerpt from:
Meet the Experts: Dr. Natthapat Benz Minchaiynunt of Alpha Medical Clinic - Prestige Online Thailand

At the 18th International Conference of the Metabolomics Society, Bruker Corporation (Nasdaq: BRKR) announced key innovations for spatial multiomics with a focus on unbiased Spatial Single-Cell Metabolomics (SSCM) for probing differential cellular phenotypes based on the metabolic signature of tissues and single cells.

Combining SSCM with the recently announced MALDI HiPLEX-IHC workflow enables in situ single cell immunometabolomics studies that integrate metabolomics-based immune reprogramming with targeted proteomics. This single-cell multiomics workflow is enabled by the new microGRID smartbeam 3D MALDI source for timsTOF fleX systems for sub-micron positioning for spatial resolution down to five micrometers (5 m), virtually eliminating any artifacts in the co-registration of MALDI molecular images with optical microscopy.

Single-cell technologies have revolutionized the understanding of heterogeneous biological processes underlying cancer, regenerative medicine, aging, and liver diseases. Studying cell-to-cell tissue variation enhances translational research, for example, in the development of better cancer research methods for the development of therapeutics targeting rare tumor cells.

Professor Theodore Alexandrov, Head of the Metabolomics Core Facility and Molecular Medicine Partnership Unit at the EMBL in Heidelberg, Germany, will lead a new project called SpaceM in the BioStudio Faculty of the BioInnovation Institute in Copenhagen, Denmark, focusing on single-cell metabolomics for drug discovery and precision medicine.

Dr. Alexandrov commented: We are in the process of developing the SpaceM technology for spatial single-cell metabolomics, developed at EMBL Heidelberg, into a platform for rapid drug discovery. As part of the BioStudio program at the BioInnovation Institute in Copenhagen, we will use a timsTOF fleX MALDI-2 imaging system for fast, sensitive, and specific in situ analyses of single cells to determine their metabolic states. In addition, the latest microGRID technology will provide us with the high spatial resolution needed to precisely interrogate single cells.

Bruker today also announced the next-generation of its advanced MetaboScape and TASQ software for metabolomic profiling and quantitation. MetaboScape 2022b now features integration of CCS-Predict Pro machine learning. Accurate and reproducible CCS values measured on the timsTOF platform can be matched to CCS values predicted from compound libraries or biotransformation algorithms, adding an orthogonal dimension for confident compound annotation.

TASQ 2022b complements the established target screening and quantitation functionality by a CCS-enabled isotope tracing workflow module. Data processing for large scale stable isotope tracer experiments is simplified as key algorithms such as the correction for naturally occurring isotopes and fractional contribution of isotopic labels are provided.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Brukers high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit http://www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005515/en/

Excerpt from:
Bruker is Ushering in the Age of Spatial Single-Cell Metabolomics - GuruFocus.com

Dr. Cato T. Laurencin is the first professor from the University of Connecticut to be elected to the Academia Europaea for his outstanding achievements as a researcher, along with his scholarship and eminence in his field. Membership to the Academia Europaea is by invite only after peer nomination and competition.I am very honored to be elected to this Academy. This further shows the importance of the field of Regenerative Engineering worldwide and its ability to bring breakthrough results aimed at ultimately helping people, said Laurencin, University Professor at UConn and the Albert and Wilda Van Dusen Distinguished Professor of Orthopaedic Surgery at UConn School of Medicine.

This year, in addition to being honored by theAcademiaEuropaea, six additional academies across the world have elected Laurencin in the past 9 months: theEuropean Academy of Sciences, theSenegalese Academy of Science and Technology, theBenin Academy ofScience andArts, theIndian Academy of Sciences, and the Royal Academy of Engineering.

Laurencin also serves as CEO ofThe Connecticut Convergence Institute for Translation in Regenerative Engineeringat UConn Health and professor of chemical engineering, materials science and engineering, and biomedical engineering at UConn.

Laurencins seminal and singular accomplishments in tissue regeneration, biomaterials science, and nanotechnology, and regenerative engineering, a field he founded, have made him the foremost engineer-physician-scientist in the world. His breakthrough achievements have resulted in transformative advances in improving human life. His fundamental contributions to materials science and engineering include the introduction of nanotechnology into the biomaterials field for regeneration.

Laurencin has received singular honors in engineering, medicine, science and technology for his work. He is the first individual in history to receive both the oldest/highest award of the National Academy of Engineering (the Simon Ramo Founders Award) and one of the oldest/highest awards of the National Academy of Medicine (the Walsh McDermott Medal). The American Association for the Advancement of Science awarded Laurencin the Philip Hauge Abelson Prize given for signal contributions to the advancement of science in the United States. He is the recipient of the National Medal of Technology and Innovation, Americas highest honor for technological achievement, awarded by President Barack Obama in ceremonies at the White House

In recognition of his breakthrough achievements in Regenerative Engineering worldwide, the American Institute of Chemical Engineers created the Cato T. Laurencin Regenerative Engineering Founders Award.

The Academy is the Pan-European Academy of Sciences Humanities and Letters. The Academys members are scientists and scholars who collectively aim to promote learning, education and research. Founded in 1988, with more than 5,000 members which includes leading experts from the physical sciences and technology, biological sciences and medicine, mathematics, the letters and humanities, social and cognitive sciences, economics and the law. The Academy also publishes the international journal the European Review.

Academia Europaea advances and propagates excellence in scholarship in the humanities, law, the economic, social, and political sciences, mathematics, medicine, and all branches of natural and technological sciences anywhere in the world for the public benefit and for the advancement of the education of the public of all ages in the aforesaid subjects in Europe. The Academy includes seventy-two Nobel Laureates, several of whom were elected to the Academia before they received the prize.

I would like to congratulate you on having been successful in the competitive membership election process, wrote Marja Makarow, president of the Academia Europea in her award letter to Laurencin.

Laurencins election to the Academy will be honored at its October 2023 annual conference in Munich.

View post:
Dr. Cato T. Laurencin First from UConn Elected to the Academia Europaea - UConn Today - UConn

Zhijian James Chen, Ph.D.

DALLAS June 16, 2022 UTSouthwestern researchers Zhijian James Chen, Ph.D., and Sihan Wu, Ph.D., are part of a team that has been awarded a Cancer Grand Challenges grant, a unique award that aims to solve some of cancers toughest problems by bringing together global teams with diverse areas of expertise.

The initiative, founded by Cancer Research UK and the National Cancer Institute, will provide 20 million pounds equivalent to about $25 million over five years to Drs. Chen and Wu and colleagues from the U.S., U.K., and Germany to learn more about a phenomenon known as extrachromosomal DNA (ecDNA) circular pieces of DNA that exist outside of a cells main DNA bound together in chromosomes.

Its a great honor to be part of this stellar team, but its also a large responsibility to be entrusted with a lot of resources to solve a difficult problem in cancer biology, said Dr. Chen, Professor of Molecular Biology and Director of the Center for Inflammation Research at UTSW, a Howard Hughes Medical Institute Investigator, and winner of the 2019 Breakthrough Prize in Life Sciences.

Sihan Wu, Ph.D.

Dr. Chen is one of the worlds leading investigators into innate immunity. His discovery of the cGAS (cyclic GMP-AMP synthase) enzyme, which triggers a pathway that activates the bodys immune system, has opened the door for development of drugs designed to modulate an immune response and fight diseases such as lupus and cancer.

Its a unique and unprecedented opportunity to conduct multi-disciplinary studies focusing on ecDNA, to understand how ecDNA-driven cancers interact with the immune system, said Dr. Wu, Assistant Professor at Childrens Medical Center Research Institute at UTSW.

Dr. Wu, a leading scientist in the ecDNA field, is one of the pioneers who revealed the physical shape and molecular functions of ecDNA in cancer, laying the foundation for the modern biology of ecDNA.

Dr. Chen and Dr. Wu plan to use the funds from Cancer Grand Challenges to better understand whether cGAS detects ecDNA. One of the mysteries of ecDNA in cancers, explained Dr. Chen, is why it doesnt trigger immune activity. The two scientists aim to discover what mechanisms cancer cells use to evade immune detection, which eventually could lead to new ways to treat cancers with immunotherapy.

Their team is being led by Paul Mischel, M.D., Professor of Pathology at Stanford University, and includes scientists from University of California San Diego, The Scripps Research Institute, Fred Hutchinson Cancer Center, New York University Langone Health, Jackson Laboratory for Genomic Medicine, University College London, Queen Mary University London, University of Cambridge, University College London, and Max Delbruck Center for Molecular Medicine and Charit Berlin.

Dr. Chen is the George L. MacGregor Distinguished Chair in Biomedical Science. Dr. Wu is a Cancer Prevention and Research Institute of Texas (CPRIT) scholar. Drs. Chen and Wu are both members of the Harold C. Simmons Comprehensive Cancer Center.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialties to more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

About Childrens Medical Center Research Institute at UTSouthwestern

Childrens Medical Center Research Institute at UTSouthwestern (CRI) is a joint venture of UTSouthwestern Medical Center and Childrens Medical Center Dallas, the flagship hospital of Childrens Health. CRIs mission is to perform transformative biomedical research to better understand the biological basis of disease. Located in Dallas, Texas, CRI is home to interdisciplinary groups of scientists and physicians pursuing research at the interface of regenerative medicine, cancer biology and metabolism. For more information, visit:cri.utsw.edu. To support CRI, visit:give.childrens.com/about-us/why-help/cri/

Read the rest here:
UTSW researchers part of winning global team in Cancer Grand Challenges - UT Southwestern